Business Context and Reporting Period
This Form 8-K Current Report was filed by Nuvilex, Inc. (not Pharmacyte Biotech, Inc.) on September 29, 2014. The report details significant corporate governance changes, including the resignation of key officers and directors effective October 1, 2014, and the subsequent entry into material consulting and stock option agreements.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The financial data present relates exclusively to compensation arrangements for departing executives:
- Patricia Gruden: $10,000 monthly cash compensation; option to purchase 10,000,000 shares at $0.19/share.
- Timothy Matula: $10,000 monthly cash compensation; option to purchase 10,000,000 shares at $0.19/share.
- Richard M. Goldfarb: Compensation consists solely of an option to purchase 5,000,000 shares at $0.19/share (no cash compensation specified).
Material Changes
The primary material changes involve the departure of three senior individuals and the restructuring of their roles:
- Patricia Gruden: Resigned as CFO, Treasurer, Secretary, Board Member, and Chairman. Transitioned to a consultant role with a 2-year agreement.
- Timothy Matula: Resigned as President of Medical Marijuana Sciences, Inc. (a subsidiary) and as a Director. Transitioned to a consultant role with a 2-year agreement.
- Richard M. Goldfarb: Resigned as a Board Member, with the effective date to be determined by the CEO. Transitioned to a consultant role with a 1-year agreement.
- Robert Bowker: Resigned as a Board Member effective October 1, 2014, with no replacement agreement detailed in this text.
Outlook, Risks, and Unusual Items
Management Commentary and Governance: The Board adopted Amendment No. Two to the Bylaws on October 1, 2014. This amendment revises notice requirements for calling special board meetings and explicitly allows the Company to accept contracts for services as consideration for issuing Common Stock.
Risks and Contingencies: The new stock option agreements contain forfeiture clauses. Options will be terminated if the consulting agreements are terminated for "Cause," if the individuals breach restrictive covenants (non-competition, confidentiality), or if they fail to provide required services.
Investor Verification Checklist
- Verify the exact effective date of Richard M. Goldfarb's resignation, as it is pending CEO determination.
- Confirm the total number of shares authorized for issuance under the new option agreements (25,000,000 total) and the potential dilution impact.
- Review the full text of the attached consulting agreements (Exhibits 10.1 through 10.6) for specific service deliverables and termination conditions.
- Check subsequent filings to identify the replacement for the Chairman, CFO, and Treasurer positions vacated by Patricia Gruden.